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The pandemic influenza A/H1N1 outbreak resulted in 18,449 deaths in over 214 countries.
In Taiwan, the influenza rapid test, an in vitro diagnostic device (Flu-IVD), only requires
documented reviews for market approval by the Taiwan Food and Drug Administration.
The purpose of this study was to investigate the analytical sensitivity and specificity of Flu-
IVDs used in Taiwan. Analytical sensitivity and specificity tests were performed for
influenza antigens A/California/7/2009 (H1N1) virus, A/Victoria/210/2009 (H3N2) virus, B/
Brisbane/60/08 virus, and human coronavirus OC43. A total of seven domestic and 31 im-
ported Flu-IVD samples were collected, of which, 20 samples had inadequate labeling,
including those with removed package inserts or incorrect insert information. The
analytical sensitivity of Flu-IVDs for A/H1N1, A/H3N2, and Flu B was 500e1000 ng/mL,
1000 ng/mL, and 1000 ng/mL, respectively. For the 50% cell culture infective dose (CCID50)
label, the average A/H1N1 and A/H3N2 sensitivity for Flu-IVDs was log10 5.8  0.5 and log10
6.6  0.5 CCID50/mL, respectively. As to the specificity test, no product cross-reacted with
human coronavirus OC43. This study provides important information on the Flu-IVD
regulation status and can thus help the government formulate policies for the regulation
of in vitro diagnostic devices in Taiwan.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.Open access under CC BY-NC-ND license. 1. Introduction these influenza viruses [2]. A novel human influenza A (H1N1)In 1998, a triple-reassortant swine influenza virus from
human, swine, and avian genomes was identified in the USA
[1]. Ten years later, humans were found to be infected withDivision of Research and
. Wang).
ministration, Taiwan. Publivirus caused aworldwide respiratory disease outbreak in April
2009. The major transmission route for influenza virus is via
respiratory droplets released while coughing [3e5]. Influenza
virus replicates in the epithelial cells of the upper respiratoryAnalysis, Food and Drug Administration, Ministry of Health and
shed by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license. 
Table 1 e List of domestic influenza in vitro diagnostic
devices collected in Taiwan.
Product name Lot no. Manufacturing
country
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other cells. The clinical manifestations of influenza are fever,
headache, myalgia, fatigue, rhinorrhea, sore throat, and
cough. The impact of influenza outbreaks is much higher in
children than in adults. Most healthy adults will recover after
3e7 days [6e8]. Influenza A/H3N2 was the predominant
serotype during the 2010e2011 season, whereas the A/H1N1
2009 virus still cocirculated with the A/H3N2 and influenza B
strains [9]. The pandemic influenza A/H1N1 outbreak resulted
in over 18,449 deaths in over 214 countries until 2012 [10,11].
Conventional diagnostic testing of influenza virus included
virus incubation and nucleic acid amplification test. Virus
incubation is the first method used to diagnose virus in-
fections, while it takes about 7 days to amplify the virus in the
host cells. A nucleic acid amplification test is the most sen-
sitive method to detect virus infection, but pretreatment of
the sample, including virus isolation and nucleic extraction,
still requires about 1 day. The above methods are not suitable
for the rapid screening of influenza virus [12]. In vitro diag-
nostic devices (IVDs) play crucial roles in disease diagnosis
because of their rapid and convenient properties. Diagnostic
accuracy of IVDs is dependent on their sensitivity and speci-
ficity. A previous study evaluated the 3M rapid detection test
for the respiratory syncytial virus, and found the sensitivity
and specificity of the device to be 74% and 100%, respectively
[13]. In April 2011, a study conducted by Iregbu et al [14] on the
performance of Dual Path Platform testing kits revealed a
sensitivity of 100% and specificity of 99.5%. By contrast, a
study by Shrivastava et al [15] reported that the commercial
Dengue NS1 antigen kit had a sensitivity of 26% against 91
clinical samples. Few studies have reported the sensitivity of
influenza IVDs (Flu-IVDs) in detecting influenza A. These
previous studies used four commercialized rapid test kits
[16e20].
Flu-IVD rapid test kits are based on immunochromato-
graphic tests. This type of IVD is designed for easy and fast
operation, which enables physicians to obtain results at the
primary influenza screening sites. The Flu-IVD rapid test kits
have been classified into a low-risk class I device according to
the medical device regulation and risk assessment in Taiwan.
They are applied and approved by the Taiwan Food and Drug
Administration (FDA) for pre-market approvals via the fast
tract pathway, that is, they are exempt from the substantial
performance review.
In this study, we collected Taiwan-FDA-approved Flu-IVDs
from the Taiwanese market and evaluated their performance.
The standard antigens prepared from viral cultures and pu-
rified hemagglutinins (HAs) were used to evaluate the
analytical sensitivity and specificity of the Flu-IVDs. The re-
sults represent the actual responses of these rapid test kits
and provided references for future amendments in
regulations.Firstep Influenza A&B
Test Card
10072609 Taiwan
Formosa One Sure Flu
A/B Rapid Test Kit
MS19A21 Taiwan
MS19A71
MS19A81
Long TERM Influenza A&B 990510-06 Taiwan
990629-01
990928-072. Methods
2.1. Analytical standard
The international standards for HA and influenza virus were
used as the analytical standards for the Flu-IVDs sensitivitytest. For HA standards, the Influenza Antigen A/California/7/
2009 (H1N1, NYMCX-179A, Egg derived, NIBSC code: 09/146), A/
Victoria/210/2009 (H3N2, NYMCX-187, NIBSC code: 10/102),
and Influenza B/Brisbane/60/08 Antigen Reagent (NIBSC code:
08/352) were obtained from the National Institute for Biolog-
ical Standards and Control (Potters Bar, Herts, UK). The
influenza A/Taiwan/9042/2008 (H1N1) virus with 108.23 50%
cell culture infective doses (CCID50)/mL and A/Taiwan/439/
2009 (H3N2) virus with 106.3 CCID50/mL from Chang Geng
Universitywere used as influenza viral particle standards. The
human coronavirus OC43 (HCoV-OC43, ATCC VR-759) was
obtained from American Type Culture Collection (Manassas,
VA, USA).2.2. Specimen collection
Flu-IVDswere purchased directly from themanufacturers and
local distributors in 1e3 different lots. The product name, lot
number, andmanufacturing country of each Flu-IVD are listed
in Tables 1 and 2.2.3. Appearances and label survey
The appearance of the products and the labels on the Flu-IVDs
were compared with information on their licenses, including
Chinese and English names, license numbers, name of
manufacturer, address of manufacturer, and expiration dates.2.4. Sensitivity analysis
Sensitivity was assayed as described previously, with modi-
fications [21]. The sensitivity of the collected Flu-IVDs was
specified as HA concentrations or CCID50. The HA standards
consisting of Influenza Antigens A/California/7/2009 (H1N1),
A/Victoria/210/2009 (H3N2) and B/Brisbane/60/08 were diluted
individually to 0.25e50,000 ng/mL, 0.25e13,000 ng/mL, and
0.25e13,500 ng/mL, respectively, with the dilution buffer
provided in the Flu-IVDs. Additionally, the influenza A/
Taiwan/9042/2008 (H1N1) and A/Taiwan/439/2009 (H3N2) vi-
ruses were prepared from infected rhabdomyosarcoma (RD)
cells and diluted to concentrations of 101.3e105.3 CCID50/mL
and 101.23e107.23 CCID50/mL, respectively, with minimum
essential medium (Gibco, Grand Island, NY, USA). The sensi-
tivity assay of each Flu-IVD, including the positive and nega-
tive controls, was carried out by following the instructions in
Table 2 e List of imported influenza in vitro diagnostic
devices collected in Taiwan.
Product name Lot no. Manufacturing
country
DIAQUICK influenza Ag Dipstick 1301/069039-U Austria
BD Directigen EZ Flu A þ B 9341551 China
Feng Chi Kaibilia Influenza
A þ Influenza B nucleoprotein
antigen Rapid Test Kit
AB091102 China
AB100501
AB100502
On-call Influenza A&B Rapid
Test Strip
FLU00880002 China
Actim Influenza A&B Test Kit 0021825 Finland
0021888
0081929
“Jolex” BioTracer
Influenza A&B
11321910 Korea
11321911
11321912
Bioland NanoSign Influenza
A/B Antigen
INF101109 Korea
“SD” Influenza Ag 069041 Korea
069042
069043
EZ-TRUST Influenza A&B
Rapid Screen Test
W7100401 Singapore
W7100402
W7100403
Linear Influenza A þ B rapid
test Kit
Z-031 Spain
Z-036
Z-037
VEGAL Influenza A þ B Z031 Spain
Binax NOW Influenza A&B 43842 USA
Genzyme Influenza A&B Test 091511A USA
Meridian TRU FLU Test 731230.075 USA
731230.082
Applied Biotech Influenza
A þ B test
911067 USA
912150
1008156
Unipath Clearview Exact
Influenza A&B
FLU9090087 UK
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technicians performed the experiments.Table 3 e Evaluation of sensitivity of Flu-IVDs for
hemagglutinin concentrations.2.5. Specificity analysis
HCoV-OC43 was prepared from infected MRC-5 cells. The
extract containing 1  107 CCID50/mL of virus was used to
evaluate the specificity of Flu-IVDs. The experimental protocol
was carried out in accordance with the operation manuals of
each Flu-IVDs. Two independent and well-training re-
searchers carried out the experiments.Source Standard
type
Product
codea
Sensitivity results (ng/mL)
H1N1 H3N2
Import Flu A A 500 1000
B 500 1000
C 1000 1000
Flu B A 1000
B 1000
C 1000
a Seven products of three Flu-IVD licenses (code AeC) were
analyzed.3. Results and discussion
Flu-IVDs are classified as class 1 medical devices, indicating
that the license could be easily obtained through document
reviews. Therefore, the quality of Flu-IVDs needs to be
investigated and monitored. In Taiwan, suspected influenza
patients are immediately tested with Flu-IVDs at the primary
screening site in epidemics areas. The therapeutic strategies
are divided into two parts based on the test results. If the testresult is positive and the patient exhibits influenza-like
symptoms, the patient is immediately administered antiviral
drugs such as osletamivir (Tamiflu) and continuously moni-
tored with Flu PCR test kits. However, negative test results
indicate that the patient only has a common cold, and no
antiviral drug treatment is given. The use of Flu-IVDs plays a
crucial role in controlling influenza epidemics. Hence, false-
positive outcomes may cause inappropriate administration
of osletamivir, which could lead to future challenges in the
prevention of influenza. Prior to 2009, several commercial Flu-
IVD rapid test kits were approved in Taiwan. However, after
the influenza A/H1N1 pandemics in 2009, the Taiwan FDA
issued many licenses for similar products. We thus aimed to
examine the analytical sensitivity and specificity of Flu A-IVDs
used in Taiwan.3.1. Specimen collection
A total of 38 products with 19 Flu-IVD licenses were collected,
of which sevenwere domestic and 31were imported Flu-IVDs.
Product labels of 20 samples did not comply with the regula-
tions in Taiwan FDA. For example, those with unsatisfactory
product labels lacked a product name and/or license number
on the packaging or buffer containers. Some products had no
package insert in them, and some package inserts did not
indicate the sensitivity of the product. The percentage of un-
satisfactory product labels in domestic and imported kits was
43% (3/7) and 55% (17/31), respectively.3.2. Analytical sensitivity
Based on the reaction principles, the detecting targets of the
collected samples were grouped as HA and viral particles. The
Flu-IVDs belonging to the HA group were evaluated for their
analytical sensitivity with the World Health Organization
(WHO) international standard Influenza Antigens A/Califor-
nia/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Bris-
bane/60/08. As shown in Table 3, seven products of three Flu-
IVD licenses (AeC) that were manufactured in the USA and
Spain used HA concentrations as their sensitivity label. The
analytical sensitivity of these Flu-IVDs against A/H1N1, A/
H3N2, and Flu B was 500e1000 ng/mL, 1000 ng/mL, and
1000 ng/mL, respectively. For A/H1N1 detection, products A
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 2 ( 2 0 1 4 ) 2 7 9e2 8 4282and B displayed higher analytical sensitivity than product C.
The sensitivity results for A/H3N2 and Flu B were identical in
these samples. We obtained seven products from three do-
mestic Flu-IVDs (DeF) and 17 products from eight Flu-IVDs
(GeN) imported from China, the UK, Finland, Singapore,
USA, and Korea with CCID50 labels. In the past 5 years, type A/
Taiwan/439/2009 (H3N2) and type A/Taiwan/9042/2008 (H1N1)
were the two main strains of influenza outbreak in Taiwan.
Hence, these two virus strains were used as influenza viral
particle standards for CCID50 test [22]. The averages of A/H1N1
and A/H3N2 sensitivity were log10 5.8  0.5 CCID50/mL and
log10 6.6  0.5 CCID50/mL, respectively. In Fig. 1, the unbroken,
broken, and dotted lines represent the mean, mean  1
standard deviation (SD) and mean  2 SD in the sensitivityD E F G H I J K L M N
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Fig. 1 e Evaluation of the sensitivity of Flu-IVDs for H1N1
(A) and H3N2 (B) in 50% cell culture infective dose.
Unbroken (e), broken (——), and dotted lines (......) indicate
the mean, mean ± SD values, and mean ± 2 SD values,
respectively. Product codes are designated by a letter from
D to N. Seven products of three domestic Flu-IVD licenses
(code DeF) and 17 products of eight imported Flu-IVD
licenses (from code GeN) were analyzed.
Flu-IVD [ influenza in vitro diagnostic device;
SD [ standard deviation.tests, respectively. For A/H1N1, the sensitivity of all products
was within mean  1 SD (Fig. 1A). As to A/H3N2 sensitivity,
however, the products E, I, L, and M fell into the mean  2 SD
range (Fig. 1B). Seven products fromfive imported Flu-IVDs did
not have test sensitivity labeling. Therefore, HA concentra-
tions were used to determine their sensitivities. In Table 4,
the sensitivities of these seven samples against H1N1, H3N2,
and Flu B were 500e1000 ng/mL, 500e3250 ng/mL, and
1000e6750 ng/mL, respectively.
Previous researchers have used clinical specimens to
monitor the clinical performance of Flu-IVDs. A study by
Drexler et al [17] found that BinaxNow Influenza A&B Rapid
Test Kits had a poor clinical sensitivity; the sensitivity was
11.1% for the pandemic (H1N1) 2009 virus (16 positive cases
against 144 polymerase-chain-reaction-confirmed cases). A
study by Uyeki et al [20] also showed that the QuickVue
Influenza A þ B Test had a low sensitivity (27%) for the
detection of both influenza A and B viruses. The Center for
Disease Control and Prevention screened 45 specimens with
positive results for novel influenza A (H1N1) using Directigen
EZ Flu A þ B and obtained a sensitivity of 49% [23].
We assumed that one of the reasons for the discrepancies
was that the human epidemic strains of influenza viruses
used in the Flu-IVDs did not match the current influenza virus
outbreak strains. Pandemic influenza virus strains varied
from year to year and from country to country. For example,
the influenza A/Texas/1/77 strain was used as the master
influenza virus strain to develop themonoclonal antibodies in
the BinaxNow Influenza A&B Rapid Test; however, the major
virus strain that caused the influenza outbreak in Taiwan was
the type A/Taiwan/439/2009 (H3N2) and type A/Taiwan/9042/
2008 (H1N1). Other Flu-IVDs failed to mention the master
influenza virus strain used in their preparations. Therefore,
inappropriate master influenza virus strains used in the Flu-
IVD preparations may contribute to the low detection sensi-
tivity. Moreover, studies have shown that analytical sensi-
tivity did not directly reflect the clinical sensitivity on patient
specimens. The analytical sensitivity of influenza H5N1
detection and seasonal influenza was the same, although
their clinical performances were poor [23,24]. ManufacturersTable 4 e Unlabeled sensitivity of Flu-IVDs.
Source Standard
type
Product
codea
Results (ng/mL)
H1N1 H3N2
Import Flu A O 500 500
P 1000 6500
Q 500 3250
R 500 500
S 500 500
Flu B O 1000
P 1000
Q ND
R 1000
S 6750
ND ¼ not detected.
a Seven products of five Flu-IVD licenses (code OeS) were
analyzed.
Table 5 e Specificity results of all influenza in vitro
diagnostic devices.
Test virus Cross-reactivity Specificity rate
Human coronavirs-OC43 0/38 100%
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pandemic influenza virus strains to be used in their prepara-
tion of the Flu-IVDs in order to improve the quality. We also
suggest that the class level for Flu-IVDs in Taiwan for gov-
ernment regulations be elevated so that the government can
monitor the quality of IVDs using a lot release system.
Furthermore, Taiwan FDA should establish a reference or
proficiency panel to evaluate in vitro Flu-IVDs in the near
future.3.3. Analytical specificity
Patients suffering from respiratory illness such as cough,
asthma, and emphysema are usually diagnosed with acute
respiratory tract infections. Viruses such as influenza virus,
coronavirus, and respiratory syncytial virus commonly cause
respiratory tract infections [25]. Several studies have con-
ducted a specificity test by real-time polymerase chain reac-
tion analysis for different respiratory-tract-infection-related
viruses [26,27]. The specificity of Flu-IVDs played an important
role in the selective interaction of influenza A and B viruses.
According to the epidemiological studies, HCoV caused >15%
of common colds in adults, of which OC43 was the most
common [28]. Hence, we used the common HCoV-OC43 to
determine the specificity of Flu-IVDs in this study and the
result showed that not all Flu-IVDs cross-reacted with HCoV-
OC43, suggesting good specificity (Table 5).
In conclusion, seven domestic and 31 imported Flu-IVDs
were collected to analyze the sensitivity and specificity.
Analytical sensitivity of Flu-IVDs for A/H1N1, A/H3N2, and Flu
B was 500e1000 ng/mL, 1000 ng/mL, and 1000 ng/mL, respec-
tively. Average sensitivity of A/H1N1 and A/H3N2 for Flu-IVDs
was log10 5.8  0.5 CCID50/mL and log10 6.6  0.5 CCID50/mL,
respectively. No products cross-reacted with HCoV-OC43. Our
results could provide more information for future policy-
making strategies and preparedness against seasonal and
pandemic influenza.Acknowledgments
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